TDI is the world's leaving preclinical ALS therapeutic screening organization. Our
experience includes screening hundreds of compounds thoroughly. We have experience
working with the top pharmaceutical and biotechnology companies in the world in
screening compounds in preclinical models of ALS. We have worked closely with these
teams to get them an answer they can believe.
By working with TDI to screen your candidate therapeutic(s) you will gain access
to more than a decade of experience in helping the leading
drug companies in the world more promising treatments for this neurodegenerative
disease forward. All of our preclinical drug screening clients receive:
We’ll work with you to understand the unique characteristics of your candidate therapeutic(s)
and then design the appropriate assays and experiemnts needed to know what effect if any it
on the onset and progression. Several of our preclinical animal models have similar
pathologies yet diverse genetic associations with multiple human
neurological diseases. This provides a unique opportunity to characterize your lead
candidates across multiple potential disease indications inlcuding ALS, Alzheimer's, and
TDI Services is a unique disease modeling and drug development concierge service
designed specifically for academics, non-profit foundations as well as biotechnology
and pharmaceutical companies. The services we offer are crucial to your success
whether you are looking to complement your organization's existing scientific capabilities
or access world-class talent on a contract basis as part of your virtual biotech
We value quality and efficiency above all else and will help you arrive at critical
decision making milestones in your quest to advance your projects.
Click here to contact us or to learn more
about our gene expression,
or drug validation platforms.
Historically the translation of preclinical findings to treatments for patients has
been disappointing in ALS due to a lack of rigorous preclinical drug testing.
ALS TDI wrote the book on what are the pitfalls in this process and how to design and
power experiments to avoid them.
Our advances in these efforts to improve preclinical drug development in ALS has
been recognized in many related fields (Nature, IOM).
Our team’s approach to preclinical drug screen is now the accepted standard for most
grant making organizations in the world. More so, nearly every compound that is
going into the clinic today has been screened using the techniques and protocols
developed by our team.
Contact Us >>